Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18190983 | 0.85 | TUBB1 (0.33) | TUBB1ALDH1A1L3MBTL1NFE2L2LMNA | |
| SCHEMBL27665453 | 0.82 | TUBB1 (0.35) | TUBB1HTR1ANFE2L2LMNAMAPK1 | |
| SCHEMBL10578058 | 0.78 | TUBB1 (0.35) | TUBB1HTR1AALDH1A1NFE2L2LMNA | |
| SCHEMBL27759581 | 0.78 | TUBB1 (0.33) | TUBB1HTR1ANFE2L2LMNAMAPK1 | |
| SCHEMBL27553534 | 0.77 | CYP17A1 (0.35) | TUBB1HTR1AALDH1A1NFE2L2LMNA | |
| SCHEMBL30630190 | 0.75 | TUBB1 (0.40) | TUBB1ALDH1A1NFE2L2LMNAMAPK1 | |
| SCHEMBL30315940 | 0.75 | TUBB1 (0.40) | TUBB1ALDH1A1NFE2L2LMNAMAPK1 | |
| SCHEMBL31467061 | 0.74 | MAPT (0.37) | TUBB1HTR1ALMNAMAPK1HTT | |
| SCHEMBL27268416 | 0.74 | TUBB1 (0.33) | TUBB1HTR1ANFE2L2LMNAMAPK1 | |
| SCHEMBL5631630 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974705-A | Preparation method of 2-bromo-4-trifluoromethoxyaniline | 阜新睿光氟化学有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-102491910-A | Method for synthesizing 2,6-dibromo-4-(trifluoromethoxy) aniline by water-phase method | YANCHENG LIMIN CHEMICAL CO LTD | 2012-06-13 | — | — | CN | disclosed |
| CN-102498096-A | Indole derivatives or pharmaceutically acceptable salts thereof | KISSEI PHARMACEUTICAL | 2012-06-13 | — | — | CN | disclosed |
| CN-100575334-C | The 2-dialkylamino alkylbiphenyl derivatives that replaces | GRUENENTHAL GMBH | 2009-12-30 | — | — | CN | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1800145-A | Substituted 2-dialkylaminoalkylbiphenyl derivatives | GRUENENTHAL GMBH (DE) | 2006-07-12 | — | — | CN | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1245376-C | Substituted 2-Dialkylaminoalkylbiphenyl Derivatives | GRUENTHAL GMBH (DE) | 2006-03-15 | — | — | CN | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| CN-1379755-A | Substituted 2-Dialkylaminoalkylbiphenyl Derivatives | GRUENTHAL GMBH (DE) | 2002-11-13 | — | — | CN | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | TUBB1 2998/4885HTR1A 7/4885ALDH1A1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.